Praxis Precision Medicines (PRAX) Q4 2025 earnings summary

Executive summary

• Achieved significant clinical and regulatory milestones in 2025, including positive readouts for ulixacaltamide, relutrigine, and vormatrigine, and accelerated development for elsunersen.

• Submitted two NDAs: ulixacaltamide for essential tremor and relutrigine for SCN2A/8A DEEs, following positive Phase 3 and registrational data; commercial launches are being prepared.

• Multiple pivotal trial readouts expected in the next 12-18 months, including POWER1 (vormatrigine) and EMBRAVE (elsunersen).

• Transitioning from a clinical-stage to a commercial-stage company with robust pre-launch activities and accelerated plans through 2026.

• Four late-stage assets have a combined revenue potential exceeding $20 billion.

Financial highlights

• Q4 2025 operating expenses were $97M ($77.5M R&D, $19.5M G&A), up from $71.4M in Q4 2024.

• Full-year 2025 operating expenses totaled $326M, compared to $209M in 2024, driven by increased R&D investment.

• Cash and investments totaled $926M at year-end 2025, up from $469M a year earlier, boosted by public offerings.

• January 2026 public offering added $621M, bringing pro forma cash to ~$1.5B, funding operations into 2028.

• Net loss for 2025 was $303.3M, compared to $182.8M in 2024.

Outlook and guidance

• Expect significant increase in spending in 2026 for commercial launches and continued pipeline progress.

• Anticipate POWER1 top-line results (vormatrigine) and EMBRAVE data (elsunersen) in the next quarter; potential NDA submissions in the next two years.

• EMERALD trial for relutrigine in broad DEE to complete enrollment this year; sNDA submission targeted for 2027.

• Planning R&D and commercial days next quarter to discuss pipeline and launch strategies.

• Cash runway expected to fund operations into 2028.